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Abstract
Background: To investigate whether high blood pressure accelerates renal function decline in patients with
advanced chronic kidney disease (CKD), we studied the association of systolic (SBP) and diastolic blood pressure
(DBP) with decline in renal function and time until the start of renal replacement therapy (RRT) in patients with
CKD stages IV-V on pre-dialysis care.
Methods: In the PREPARE-1 cohort 547 incident pre-dialysis patients, referred as part of the usual care to
outpatient clinics of eight Dutch hospitals, were included between 1999 and 2001 and followed until the start of
RRT, mortality, or end of follow-up (January 1
st 2008). Main outcomes were rate of decline in renal function,
estimated as the slope of available eGFR measurements, and time until the start of RRT.
Results: A total of 508 patients, 57% men and median (IQR) age of 63 (50-73) years, were available for analyses.
Mean (SD) decline in renal function was 0.35 (0.75) ml/min/1.73 m
2/month. Every 10 mmHg increase in SBP or DBP
resulted in an accelerated decline in renal function (adjusted additional decline 0.04 (0.02;0.07) and 0.05 (0.00;0.11)
ml/min/1.73 m
2/month respectively) and an earlier start of RRT (adjusted HR 1.09 (1.04;1.14) and 1.16 (1.05;1.28)
respectively). Furthermore, patients with SBP and DBP above the BP target goal of < 130/80 mmHg experienced a
faster decline in renal function (adjusted additional decline 0.31 (0.08;0.53) ml/min/1.73 m
2/month) and an earlier
start of RRT (adjusted HR 2.08 (1.25;3.44)), compared to patients who achieved the target goal (11%). Comparing
the decline in renal function and risk of starting RRT between patients with only SBP above the target (≥ 130
mmHg) and patients with both SBP and DBP below the target (< 130/80 mmHg), showed that the results were
almost similar as compared to patients with both SBP and DBP above the target (adjusted additional decline 0.31
(0.04;0.58) ml/min/1.73 m
2/month and adjusted HR 2.24 (1.26;3.97)). Therefore, it seems that especially having SBP
above the target is harmful.
Conclusions: In pre-dialysis patients with CKD stages IV-V, having blood pressure (especially SBP) above the target
goal for CKD patients (< 130/80 mmHg) was associated with a faster decline in renal function and a later start of
RRT.
Keywords: blood pressure, chronic kidney disease stages IV-V, estimated glomerular filtration rate, pre-dialysis care,
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C h r o n i ck i d n e yd i s e a s e( C K D )a n de n d - s t a g er e n a ld i s -
ease (ESRD) are major public health problems world-
wide, because of rapidly increasing numbers of prevalent
and incident cases [1-3]. The demand for pre-dialysis
care is growing due to the increasing number of patients
with late-stage CKD. Patients on pre-dialysis care need
to be treated to slow down decline in renal function and
to postpone the start of renal replacement therapy
(RRT; dialysis and transplantation).
High blood pressure is an important independent pre-
dictor of decline in renal function in the general popula-
tion [4] and in several subgroups [5-8]. Furthermore,
high blood pressure is also a risk factor for the progres-
sion to CKD [9,10] and ESRD [11-14] in the general
population. Once a person has developed early stage
CKD, blood pressure has a persisting detrimental effect
on decline in renal function resulting in an accelerated
progression to ESRD [15-19]. However, little is known
about the association of blood pressure with decline in
renal function in patients with CKD stages IV-V on pre-
dialysis care.
Therefore, it is important to study the association of
blood pressure with progression of CKD in patients
with CKD stages IV-V on pre-dialysis care. Guidelines
f r o mt h eK i d n e yD i s e a s eO u t c o m e sQ u a l i t yI n i t i a t i v e
( K / D O Q I ) ,S e v e n t hR e p o r to ft h eJ o i n tN a t i o n a lC o m -
mittee (JNC 7), and the American Heart Association
(AHA) propose a blood pressure treatment target goal
of < 130/80 mmHg through all stages of CKD [20-22].
Because the use of this proposed treatment target goal
o f<1 3 0 / 8 0m m H gi np r e - d i a l y s i sp a t i e n t si sn o te v i -
dence based, it is important to investigate whether this
goal is indeed beneficial in this specific population.
Therefore, the aim of our study was to investigate the
association of systolic (SBP) and diastolic blood pressure
(DBP) with progression of CKD as assessed by decline
in renal function and time until the start of RRT in
patients with CKD stages IV-V on pre-dialysis care.
Methods
Study design and participants
The PREdialysis PAtient REcord-1 (PREPARE-1) study
is a follow-up study in which consecutive incident adult
patients with CKD stages IV-V were included from out-
patient clinics of eight Dutch hospitals when referred
for pre-dialysis care between 1999 and 2001. Patients
had been referred to these outpatient clinics if creatinine
clearance was below 20 ml/min. Furthermore, in these
patients the need for RRT was expected within one year.
Patients who spent less than one month on pre-dialysis
care and patients with prior RRT were excluded. The
clinical course of pre-dialysis patients was followed
through the medical charts until the start of dialysis,
transplantation, death, or January 1
st 2008, whichever
was earliest. Predefined data on demography, anthropo-
metry, and clinical symptoms were extracted from medi-
cal charts at inclusion. All available data concerning
laboratory measurements during pre-dialysis care were
extracted from the Hospital Information Systems. The
study was approved by the Institutional Review Boards
of the participating hospitals and conducted in concor-
dance with Good Clinical Practice Guidelines.
Measurements and definitions
Blood pressure and variables used for adjustment in
multivariable analyses were assessed at the first pre-dia-
lysis visit (baseline) and measured according to the stan-
dard care applied in each individual hospital. The
standard procedure for measuring blood pressure is
using a device dependent on cuff occlusion of the arm,
with the patient in sitting or lying position. The blood
pressure treatment target goal was defined as SBP < 130
mmHg and DBP < 80 mmHg according to the K/DOQI,
JNC 7, and AHA guidelines [20-22]. Estimated glomeru-
lar filtration rate (eGFR) was estimated using the abbre-
viated Modification of Diet in Renal Disease (MDRD)
formula, taking into account age, sex, race, and serum
creatinine [23]. Baseline serum creatinine measurement
was defined as the measurement closest to the start of
pre-dialysis care, within 90 days before and 14 days after
the start.
Outcomes
For the present analyses, the first year of pre-dialysis
care was used as follow-up time, because blood pressure
was only assessed at baseline and blood pressure levels
can change during pre-dialysis care. Therefore, we
expect that the effect of baseline blood pressure on pro-
gression of CKD weakens after several years of follow-
up. Outcomes were decline in renal function and time
until the start of RRT. The rate of decline in renal func-
tion was estimated by fitting a regression line through
the available eGFR measurements for each individual
patient. This resulted in slopes expressing the monthly
loss of eGFR. eGFR measurements between one month
prior to inclusion and one year after inclusion were
used and at least two measurements had to be available
to estimate the rate of decline. Patients with eGFR mea-
surements only available between one month prior to
inclusion and one month thereafter were excluded from
the analyses for decline in renal function (n = 20). The
start of RRT was defined as starting dialysis or being
transplanted within the first year of pre-dialysis care.
Statistical analyses
Continuous data were expressed as mean (standard
deviation, SD) and skewed data as median (boundaries
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Page 2 of 10of interquartile range, IQR). Baseline characteristics
were presented for the total study population and strati-
fied for patients below or above the blood pressure
treatment target goal. SBP and DBP were both analyzed
in steps of 10 mmHg increase and in categories. We
used clinically relevant categories for SBP (< 130 (refer-
ence group), 130-149, 150-169, 170-189, and ≥ 190
mmHg) and for DBP (< 80 (reference group), 80-89, 90-
99, and ≥ 100 mmHg). The reference categories chosen
were based on the treatment target goal of < 130/80
mmHg. Furthermore, the range of the SBP and DBP
categories (steps of 10 and 20 mmHg respectively) were
selected by using the distribution of these variables, to
end up with enough power in each category. Addition-
ally, SBP and DBP were combined based on the treat-
ment target goal of < 130/80 mmHg. The additional
effect of having DBP above 80 mmHg on top of having
SBP above 130 mmHg, compared to the single effect of
SBP ≥ 130 mmHg or DBP ≥ 80 mmHg, was investi-
gated. For this analysis, patients were stratified into four
categories based on the combination of SBP and DBP (<
130/< 80 (reference group), ≥ 130/< 80, < 130/≥ 80, and
≥ 130/≥ 80 mmHg).
A linear regression analysis was used to assess the
association of blood pressure with decline in renal func-
tion during the first year of follow-up. Multivariable
analyses were used to adjust for the possible confoun-
ders age, sex, race, smoking, primary kidney disease,
presence of cardiovascular disease (CVD; angina pec-
toris, coronary disease, and/or myocardial infarction),
and presence of diabetes mellitus (DM).
The Kaplan-Meier method was used to estimate the
crude risk and a Cox proportional hazard regression
analysis was used to estimate the adjusted risk of start-
ing RRT during the first year of pre-dialysis care. The
risk of starting RRT was adjusted for the same confoun-
ders used in the multivariable linear regression analyses.
The time from the first pre-dialysis visit until the start
of RRT or end of the first year of follow-up was used in
the Cox proportional hazard regression as follow-up
time. Mortality and lost to follow-up were censored
events. All p-values are two-tailed and p < 0.05 was con-
sidered statistically significant. Data were analyzed with
PASW/SPSS version 17.
Multiple sensitivity analyses were performed. First,
sensitivity analyses were performed with only the first
six months or with complete follow-up (until January 1
st
2008) instead of the first year of follow-up, to investigate
whether differences in follow-up time lead to different
results. Second, a sensitivity analysis was performed with
SBP and DBP stratified in quartiles and quintiles to
make sure that the associations found are robust and
not dependent on the choice of categories. Third, it can
be argued that our analyses should be additionally
adjusted for proteinuria, hemoglobin, and baseline
eGFR. However, data regarding proteinuria, hemoglobin,
and baseline eGFR were not available for all patients
included in the analyses (n = 405, n = 444, and n = 445
respectively). Therefore, adjusting for these variables was
only performed as a sensitivity analysis, in order to
maintain power.
Results
Baseline characteristics
From the 547 incident pre-dialysis patients included,
525 patients had no prior RRT and spent more than
one month on pre-dialysis care. SBP and DBP measure-
ments at baseline were present for 508 patients and for
436 patients two or more eGFR measurements were
available to estimate the rate of decline in renal func-
t i o n .O ft h e s e5 0 8p a t i e n t s ,8 9 %h a dS B Pa n d / o rD B P
above the blood pressure treatment target goal (SBP ≥
130 mmHg and/or DBP ≥ 80 mmHg). Most of the
patients on pre-dialysis care were referred by nephrolo-
gists (76%). This percentage was the same in patients
below and patients above the target (78% and 76%
respectively, Table 1). Patients with SBP and/or DBP
above the target were older, smoked more, had a slightly
higher body mass index (BMI), lower eGFR, higher
levels of proteinuria, and a higher prevalence of CVD
(Table 1). At baseline, patients with an available esti-
mated rate of decline in renal function (n = 436) were
slightly older, had a higher eGFR, lower levels of protei-
nuria, and less co-morbidities, than patients without
available eGFR data (n = 72).
Of all patients, 92% were treated with anti-hyperten-
sive drugs at baseline. Patients below the blood pressure
treatment target goal were primarily prescribed angio-
tensin converting enzyme (ACE)-inhibitors and/or
diuretics whereas patients above the target were pre-
scribed calcium-antagonists and beta-blockers just as
often (Table 2). Angiotensin II-inhibitors were pre-
scribed the least. Furthermore, the number of anti-
hypertensive drug types was higher in patients above the
blood pressure treatment target goal than in patients
below the target. Of the patients treated with anti-
hypertensive drugs, only 11% achieved the blood pres-
sure treatment target goal of < 130/80 mmHg.
Decline in renal function
The median (IQR) number of available eGFR measure-
ments during the first year of follow-up was 9 (6-13)
and 98.6% of the patients had three or more eGFR mea-
surements. In the total group of 436 patients, mean
(SD) decline in renal function was 0.35 (0.75) ml/min/
1.73 m
2/month. Mean (SD) decline in renal function
was not dependent on the number of eGFR measure-
ments and was 0.37 (0.89), 0.38 (0.62), 0.41 (0.72), and
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2/month for patients with 2-6,
7-9, 10-13 and ≥ 14 eGFR measurements (quartiles)
respectively. The analysis of SBP in steps of 10 mmHg
showed a linear association, every 10 mmHg increase in
SBP resulted in an accelerated decline in renal function
(crude additional decline 0.03 (0.01;0.06) ml/min/1.73
m
2/month, Table 3). The analysis of SBP stratified in
categories showed similar results, every consecutive
Table 1 Demographic, anthropometric, and clinical characteristics at baseline for the total study population and
stratified for reaching the blood pressure treatment target goal
All
n = 508
Below target
Δ
n=5 8
Above target
Δ
n = 450
Age (years) 63 (50-73) 55 (45-71) 64 (50-73)
Sex (% men) 57 57 56
Caucasian (%) 97 97 96
BMI (kg/m
2)* 26 ± 5 25 ± 4 26 ± 5
Smokers/quitters < 1 year before inclusion (%) 56 50 57
Primary kidney disease (%)
Diabetes mellitus 17 16 17
Glomerulonephritis 10 14 9
Interstitial nephritis 16 17 15
Renal vascular disease/nephrosclerosis 23 17 23
Baseline eGFR (ml/min/1.73 m
2)
† 13.1 ± 5.8 14.0 ± 6.0 13.0 ± 5.7
Proteinuria (g/24 h)
‡ 2.0 (0.7-3.9) 1.1 (0.6-2.9) 2.2 (0.8-4.0)
Hemoglobin (g/dl)
§ 11.3 ± 1.6 11.4 ± 1.8 11.3 ± 1.6
Co-morbidities (%)
Anemia
· 47 46 47
Cardiovascular disease
g 36 28 37
Diabetes mellitus 27 24 27
Malignancy 11 10 11
Referral to pre-dialysis care by nephrologist (%) 76 78 76
Median with boundaries of interquartile range (IQR) is given for age and proteinuria and for the other continuous variables mean ± standard deviation (SD) is
given.
Δ Below the target was defined as SBP < 130 and DBP < 80 mmHg and above the target as SBP ≥ 130 and/or DBP ≥ 80 mmHg. * Available for 472
patients.
† estimated glomerular filtration rate (eGFR) calculated with the abbreviated Modification of Diet in Renal Disease (MDRD) formula and available for 445
patients.
‡ Available for 405 patients.
§ Available for 444 patients.
· Defined as a hemoglobin level < 11 g/dl.
g Defined as the presence of angina pectoris,
coronary disease, and/or myocardial infarction.
Table 2 Blood pressure characteristics at baseline for the total study population and stratified for reaching the blood
pressure treatment target goal
All
n = 508
Below target
Δ
n=5 8
Above target
Δ
n = 450
Systolic blood pressure (mmHg) 152 ± 27 114 ± 12 157 ± 25
Diastolic blood pressure (mmHg) 83 ± 14 68 ± 8 85 ± 13
Anti-hypertensive drug types (%)
ACE-inhibitor 43 60 40
Angiotensin II-inhibitor 20 10 21
Beta-blocker 39 31 40
Calcium antagonist 45 22 48
Diuretics 48 52 48
Other* 14 7 15
Number of anti-hypertensive drug types (%)
08 9 8
12 6 3 5 2 4
22 8 3 3 2 8
≥ 33 8 2 3 4 0
Systolic (SBP) and diastolic blood pressure (DBP) are presented as mean ± standard deviation (SD).
Δ Below the target was defined as SBP < 130 and DBP < 80 mmHg and above the target as SBP ≥ 130 and/or DBP ≥ 80 mmHg. * Defined as the prescription of
alpha blocker, vasodilator, and/or central working agent.
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(mean (SD) decline 0.22 (0.74) ml/min/1.73 m
2/month)
resulted in an accelerated decline in renal function
(Table 3).
Every 10 mmHg increase in DBP also resulted in an
accelerated decline in renal function (crude additional
decline 0.07 (0.02;0.12) ml/min/1.73 m
2/month, Table
3). Furthermore, every consecutive category above the
reference category of < 80 mmHg (mean (SD) decline of
0.26 (0.90) ml/min/1.73 m
2/month) resulted in an accel-
erated decline in renal function. However, the most pro-
nounced decline in renal function was present in
patients with DBP ≥ 100 mmHg.
Using the blood pressure treatment target goal (SBP <
130 mmHg and DBP < 80 mmHg) showed that patients
with SBP and/or DBP above the target had an acceler-
ated decline in renal function compared to patients with
SBP and DBP below the target (mean (SD) decline 0.13
(0.85) ml/min/1.73 m
2/month). Adjustment for confoun-
ders did not change these results essentially (Table 3).
Start of Renal Replacement Therapy
During the first year of follow-up, of all patients 23%
started hemodialysis and 22% peritoneal dialysis, 1%
was transplanted, 5% died, 1% was lost to follow-up
while 48% were still on pre-dialysis care. Median (IQR)
follow-up time was 351 (144-365) days, while follow-up
time in patients starting RRT was 145 (87-234) days. In
patients below and above the blood pressure treatment
target goal at baseline, mean eGFR was 6.7 and 8.2 ml/
min/1.73 m
2 at the start of RRT respectively. The crude
association of SBP and DBP categories with time until
the start of RRT is shown in Figure 1A and 1B respec-
tively. Table 4 shows the crude and the adjusted hazard
ratios (HRs) for every 10 mmHg increase in SBP and
DBP, and for clinically relevant blood pressure cate-
gories compared to the reference category of SBP < 130
mmHg or DBP < 80 mmHg respectively. Patients with
higher SBP had an earlier start of RRT. On a continuous
scale, every 10 mmHg increase in SBP resulted in an
earlier start of RRT (crude HR 1.08 (1.03;1.13)). Further-
more, the adjusted risk of starting RRT was 1.60 fold
higher (95% CI, 1.02;2.50) in patients with SBP 130-149
mmHg compared to patients with SBP < 130 mmHg
(Table 4). For DBP, every 10 mmHg increase resulted in
an earlier start of RRT (crude HR 1.15 (1.04;1.27)). The
analysis with categories showed that only patients with
Table 3 Association of systolic and diastolic blood pressure with decline in renal function during the first year of pre-
dialysis care
n Baseline eGFR*
(ml/min/
1.73 m
2)
Crude additional decline
(ml/min/
1.73 m
2/month)
Adjusted additional decline
†
(ml/min/
1.73 m
2/month)
Adjusted additional decline
‡
(ml/min/
1.73 m
2/month)
Systolic blood pressure (mmHg):
Per 10 436 0.03 (0.01;0.06) 0.04 (0.02;0.07) 0.04 (0.02;0.07)
< 130 79 14.0 0
§ 00
130-149 116 12.8 0.13 (-0.09;0.34) 0.15 (-0.06;0.36) 0.14 (-0.07;0.35)
150-169 125 12.7 0.14 (-0.08;0.35) 0.19 (-0.02;0.39) 0.17 (-0.04;0.38)
170-189 72 14.2 0.19 (-0.05;0.43) 0.27 (0.04;0.51) 0.24 (0.00;0.48)
≥ 190 44 13.3 0.34 (0.06;0.61) 0.44 (0.16;0.71) 0.43 (0.15;0.70)
Diastolic blood pressure (mmHg):
Per 10 436 0.07 (0.02;0.12) 0.05 (0.00;0.10) 0.05 (0.00;0.11)
< 80 122 13.4 0
g 00
80-89 151 13.7 0.08 (-0.10;0.26) 0.06 (-0.12;0.23) 0.07 (-0.11;0.25)
90-99 98 13.3 0.12 (-0.07;0.32) 0.12 (-0.08;0.31) 0.12 (-0.08;0.32)
≥ 100 65 11.9 0.29 (0.07;0.52) 0.23 (0.00;0.45) 0.22 (-0.01;0.44)
Blood pressure treatment target goal (mmHg):
< 130/< 80 47 14.2 0^ 0 0
≥ 130/< 80 75 13.0 0.21 (-0.07;0.48) 0.31 (0.04;0.58) 0.31 (0.04;0.58)
< 130/≥ 80 32 13.8 0.22 (-0.12;0.55) 0.21 (-0.12;0.54) 0.26 (-0.08;0.59)
≥ 130/≥ 80 282 13.1 0.27 (0.04;0.50) 0.30 (0.08;0.53) 0.31 (0.08;0.53)
The decline (95% confidence interval) presented for each blood pressure category indicates the additional decline in renal function compared to the reference
category (systolic blood pressure (SBP) < 130 mmHg, diastolic blood pressure (DBP) < 80 mmHg, and SBP/DBP < 130/< 80 mmHg). A negative decline is
equivalent to a slower decline in renal function.
* The mean estimated glomerular filtration rate (eGFR) in ml/min/1.73 m
2 at baseline.
† Adjusted for sex and age.
‡ Adjusted for sex, age, race, smoking, primary
kidney disease, and the co-morbidities cardiovascular disease (CVD) and diabetes mellitus (DM).
§ The mean (standard deviation, SD) decline in renal function is
0.22 (0.74) ml/min/1.73 m
2/month.
g The mean (SD) decline in renal function is 0.26 (0.90) ml/min/1.73 m
2/month. ^The mean (SD) decline in renal function is
0.13 (0.85) ml/min/1.73 m
2/month.
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Page 5 of 10DBP ≥ 100 mmHg had a pronounced earlier start of
RRT (crude HR 1.84 (1.26;2.69), Table 4 and Figure 1B).
Using the blood pressure treatment target goal (SBP <
130 mmHg and DBP < 80 mmHg) showed that patients
with SBP above the target and DBP below the target
started RRT earlier (crude HR 1.93 (1.11;3.37)) com-
pared to patients with both SBP and DBP below the tar-
g e t( T a b l e4a n dF i g u r e1 C ) .P a t i e n t sw i t hS B P<1 3 0
mmHg (below target) and DBP ≥ 80 mmHg (above tar-
get) had a similar risk of starting RRT as the reference
group (patients with SBP < 130 mmHg and DBP < 80
mmHg). Having both SBP and DBP above the treatment
target goal resulted in a higher risk of starting RRT
(crude HR 1.91 (1.16;3.16)) compared to having both
SBP and DBP below the target. Adjustment for confoun-
ders did not change these results essentially (Table 4).
Sensitivity analyses
To test the robustness of our findings, several sensitivity
analyses were performed. First, in a sensitivity analysis
with only six months of follow-up, results of the primary
analyses were confirmed and point estimates were simi-
lar. Analyses with complete follow-up showed the same
trend as in the primary analyses, however the
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Figure 1 Kaplan-Meier curve for time until the start of renal
replacement therapy. Kaplan-Meier curve for the association of
systolic (SBP), diastolic blood pressure (DBP) and the combination of
SBP and DBP with time until the start of renal replacement therapy
(RRT) during the first year of follow-up in pre-dialysis patients.
Follow-up time in months (during the first year of follow-up) on the
x-axis and the percentage of patients on pre-dialysis care on the y-
axis is plotted and stratified for SBP (A), DBP (B), and SBP/DBP (C)
blood pressure categories. The numbers below the figures give the
number of patients ‘at risk’ (n) and the events in each blood
pressure category for 3 month intervals.
Table 4 Association of systolic and diastolic blood
pressure with time until the start of renal replacement
therapy during the first year of pre-dialysis care
Events/n Crude HR Adjusted HR
† Adjusted HR
‡
Systolic blood pressure (mmHg):
Per 10 235/508 1.08 (1.03;1.13) 1.09 (1.04;1.14) 1.09 (1.04;1.14)
< 130 29/91 1 1 1
130-149 60/136 1.52 (0.97;2.36) 1.54 (0.99;2.41) 1.60 (1.02;2.50)
150-169 74/147 1.82 (1.19;2.80) 1.88 (1.22;2.90) 1.96 (1.27;3.02)
170-189 46/83 2.09 (1.31;3.32) 2.20 (1.37;3.53) 2.25 (1.40;3.63)
≥ 190 26/51 2.10 (1.24;3.57) 2.27 (1.33;3.90) 2.21 (1.28;3.80)
Diastolic blood pressure (mmHg):
Per 10 235/508 1.15 (1.04;1.27) 1.15 (1.04;1.27) 1.16 (1.05;1.28)
< 80 63/153 1 1 1
80-89 76/174 1.02 (0.73;1.43) 1.03 (0.74;1.44) 1.05 (0.75;1.48)
90-99 49/106 1.09 (0.75;1.58) 1.11 (0.76;1.62) 1.11 (0.76;1.62)
≥ 100 47/75 1.84 (1.26;2.69) 1.85 (1.26;2.71) 1.88 (1.27;2.78)
Blood pressure treatment target goal (mmHg):
< 130/< 80 17/58 1 1 1
≥ 130/< 80 46/95 1.93 (1.11;3.37) 2.03 (1.15;3.57) 2.24 (1.26;3.97)
< 130/≥ 80 12/33 1.18 (0.56;2.47) 1.18 (0.56;2.47) 1.31 (0.62;2.78)
≥ 130/≥ 80 160/322 1.91 (1.16;3.16) 1.96 (1.19;3.23) 2.08 (1.25;3.44)
The hazard ratio (HR) (95% confidence interval, CI) presented for each blood
pressure category indicates the increased risk of starting renal replacement
therapy (RRT) compared to the reference category (systolic blood pressure
(SBP) < 130 mmHg, diastolic blood pressure (DBP) < 80 mmHg, and SBP/DBP
< 130/< 80 mmHg).
† Adjusted for sex and age.
‡ Adjusted for sex, age, race, smoking, primary
kidney disease, and the co-morbidities cardiovascular disease (CVD) and
diabetes mellitus (DM).
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Page 6 of 10associations were somewhat diluted. Every 10 mmHg
increase in SBP or DBP resulted in an accelerated
decline in renal function (adjusted additional decline
0.04 (0.01;0.07) and 0.05 (0.00;0.11) ml/min/1.73 m
2/
month respectively) and an earlier start of RRT (HR
1.07 (1.03;1.11) and 1.10 (1.01;1.19) respectively). Sec-
ond, other choices of blood pressure categories showed
the same results as found in the primary analyses.
Third, when including the covariates proteinuria, hemo-
globin, and baseline eGFR in the model (sample size of
404 patients), the point estimates for decline in renal
function and time until the start of RRT remained simi-
lar. With every 10 mmHg increase in SBP or DBP,
decline in renal function accelerates (adjusted additional
decline 0.04 (0.02;0.07) and 0.07 (0.02;0.12) ml/min/1.73
m
2/month respectively) and the start of RRT is earlier
(HR 1.07 (1.01;1.13) and 1.17 (1.04;1.31) respectively).
Discussion
The results of this study show that 89% of the patients
with CKD stages IV-V starting pre-dialysis care did not
reach the blood pressure treatment target goal of SBP <
130 mmHg and DBP < 80 mmHg, even though the
majority of these patients (92%) were treated with anti-
hypertensive drugs. Both higher SBP and DBP were
associated with a faster progression of CKD. More spe-
cific, patients with SBP ≥ 130 mmHg or DBP ≥ 100
mmHg had an accelerated decline in renal function
(eGFR) during pre-dialysis care which was accompanied
by an earlier start of RRT, compared to patients with
SBP < 130 mmHg or DBP < 100 mmHg. Further analy-
sis showed that in patients with SBP above the target
goal (≥ 130 mmHg), additionally having DBP above the
target goal (≥ 80 mmHg) did not result in an accelerated
decline in renal function or an earlier start of RRT.
Our study is the first European study to report on the
association of both SBP and DBP with the progression
of CKD, as assessed by decline in renal function and
time until the start of RRT, in a well-defined population
of pre-dialysis patients with CKD stages IV-V. Every 10
mmHg increase in SBP or DBP resulted in an acceler-
ated decline in renal function (adjusted additional
decline 0.04 (0.02;0.07) and 0.05 (0.00;0.11) ml/min/1.73
m
2/month respectively). Our data are in line with the
findings of several observational studies such as the
MDRD study [24], which showed that an increased
mean arterial pressure is associated with an accelerated
decline in renal function in patients with an eGFR
between 13 and 24 ml/min/1.73 m
2. However, CKD
patients with an eGFR below 13 ml/min/1.73 m
2 were
excluded from the MDRD study because they were
likely to start dialysis before the effect of diet and blood
pressure control could be evaluated [25]. Furthermore,
patients with severe co-morbidities were excluded and
the patient population in the MDRD study consisted
mostly of patients with polycystic kidney disease. Our
patients may therefore be more representative of patient
populations as seen by treating physicians in outpatient
clinics, as our patient selection did not restrict on etiol-
ogy of the primary kidney disease, level of eGFR or
severity of co-morbidities. The results of our study also
showed that every 10 mmHg increase in SBP or DBP
respectively resulted in an adjusted 1.09 (95% CI
1.04;1.14) and 1.16 (95% CI 1.05;1.28) fold increased risk
of starting RRT earlier. These results are in line with a
study performed by Levin et al [26], who found that
every 5 mmHg increase in SBP or DBP resulted in an
earlier start of RRT (HR 1.02, 95% CI 1.00;1.04, and HR
1.05, 95% CI 1.01;1.09, respectively) in a Canadian
cohort of patients on pre-dialysis care (CKD stages IV-
V, n = 4,231).
Our data are not in line with some previous published
interventional trials on the effect of lowering blood pres-
sure in CKD patients [27-29]. These studies showed that
in patients with CKD stages III-V intensive blood pres-
sure lowering (< 130/80 mmHg versus < 140/90 mmHg)
was not beneficial on the progression of CKD, defined
as decline in renal function or time until the start of
dialysis, transplantation, death and/or doubling of serum
creatinine. There are several possible explanations for
these contradictory findings. First, the study populations
of the trials differ from our study population, because
t h et r i a l sm a i n l yc o n s i s to fpatients with CKD stage III
and our observational cohort consists of patients with
advanced stages of CKD (IV-V). Furthermore, the trials
apply many patient exclusion criteria that will result in a
relatively more healthy study population compared to
our cohort. Second, the achieved blood pressure goal in
the intensively treated patients (< 130/80 mmHg) had a
large overlap with the normal treated patients (< 140/90
mmHg). This finding suggests that blood pressure con-
trol is very difficult in patients with advanced stages of
CKD and this can explain the high percentage (89%) of
pre-dialysis patients in our cohort not reaching the
treatment target goal, which is in line with another
study [30]. It can be reasoned that blood pressure con-
trol is easier to achieve in patients with early stages of
CKD, as shown by Nakayama et al [ 3 1 ] .F i n a l l y ,t h e
trials found that the effect of lowering blood pressure
was beneficial in patients with more severe proteinuria
and our cohort mainly consists of patients with protei-
nuria (89%).
The PREPARE-1 study has potential strengths and
limitations. First, in our cohort an equal number of
patients started HD and PD and therefore the results
cannot be generalized to the United States pre-dialysis
population. Furthermore, it has been estimated that in
the general population 36-65% of the patients with an
de Goeij et al. BMC Nephrology 2011, 12:38
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Page 7 of 10eGFR below 15 ml/min/1.73 m
2 are not treated by a
nephrologist [32]. Therefore, perhaps our results cannot
be generalized to all patients with an eGFR below 15
ml/min/1.73 m
2, but only to those receiving pre-dialysis
care. However, for clinical practice our cohort is a very
representative and relevant population. Second, for esti-
mating the rate of decline in renal function, we assumed
that the decline in renal function is linear in advanced
CKD stages. It has been shown previously that linearity
o ft h ec o u r s ei ne G F Ri sap l a u s i b l ea s s u m p t i o n ,
although on theoretical grounds over a longer period of
time an exponential decline could be present [24].
Third, SBP and DBP were collected only once at the
start of pre-dialysis care. This may lead to less precision
and more variability of the SBP and DBP measurement
at baseline, possibly resulting in underestimated effects.
Furthermore, blood pressure may change during pre-
dialysis care. A time-dependent analysis with time vary-
ing blood pressure would be more accurate compared
to an analysis with only one blood pressure measure-
ment at baseline. However, such data were not available
in our study. As an alternative, we showed that when
using follow-up of six months the association of blood
pressure with decline in renal function and time until
the start of RRT remained similar, whereas the results
where somewhat diluted when using complete follow-
up. The latter may indeed suggest that blood pressure
changes over time. We chose to use the first year of fol-
low-up in our primary analyses in order to have a more
precise estimation of the association of blood pressure
with decline in renal function and time until the start of
RRT. Fourth, it is possible that the association of blood
pressure with progression of CKD is confounded by the
prognosis of patients. However, baseline characteristics
showed that referral of patients is mainly done by
nephrologists and this percentage is comparable
between patients below and above the blood pressure
treatment target goal, which may give an indication that
prognosis is similar. Furthermore, adjustment for sex,
age, race, smoking, primary kidney disease, co-morbid-
ities, hemoglobin, eGFR, and proteinuria eliminated a
part of this confounding effect, but we cannot exclude
some residual confounding of our effect measures.
Adjustment for decline in renal function prior to start-
ing pre-dialysis care was not possible, because too few
eGFR measurements were available. Fifth, the aim of
this study was to investigate the association of baseline
blood pressure with progression of CKD irrespective of
blood pressure control by medication. Therefore, the
definition of the blood pressure treatment target goal
was solely based on blood pressure and results were not
adjusted for the use of anti-hypertensive drugs. Finally,
data regarding proteinuria, hemoglobin, and baseline
eGFR were not available for all patients. Therefore, in
order to maintain power and to avoid selection bias, we
chose not to include these variables into our primary
analyses. However, after adjustment for these covariates
the point estimates for decline in renal function and
time until the start of RRT remained similar.
What could be an explanation for the found associa-
tion of hypertension with an accelerated decline in renal
function and an earlier start of RRT? Endothelial dys-
function is a pathological consequence of hypertension
[33] leading to vessel damage, causing atherosclerosis,
and subsequently arterial stiffness. Arterial stiffness in
turn can lead to an increased afterload, left ventricular
hypertrophy, reduced coronary perfusion, congestive
heart failure, and altered or reduced blood supply to tis-
sues including the kidney [34]. In pre-dialysis patients,
arterial stiffness can lead to glomerular hypertension
and thereby increased glomerular permeability and
excessive filtration of proteins. Protein ultrafiltrates are
toxic to the proximal tubules, resulting in tubular
damage and scarring. Glomerular hypertension and
increased ultrafiltration of proteins contribute to the
progression of chronic renal damage and thereby renal
function [35]. It is also possible that blood pressure
increases as the result of an accelerated decline in renal
function, resulting in a vicious circle between blood
pressure increase and decline in renal function. In our
cohort, arterial stiffness seems a plausible explanation
because with increasing pulse pressure, which is a mar-
ker for arterial stiffness, decline in renal function accel-
erated and time until the start of RRT decreased (data
not shown).
Conclusions
The proposed blood pressure treatment target goal for
patients with CKD is < 130/80 mmHg, according to the
K/DOQI, JNC 7, and AHA treatment guidelines for
hypertension in CKD patients [20-22]. The results of
our study show that pre-dialysis patients with blood
pressure below this target have the slowest decline in
renal function and the latest start of RRT. Our results
support the beneficial effect of keeping blood pressure
levels, especially for systolic blood pressure, below this
treatment target goal at the start of pre-dialysis care.
Randomized controlled trials are necessary to demon-
strate whether active blood pressure lowering below this
target is beneficial in pre-dialysis patients.
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